Depression is often explained through neurotransmitters, stressful experiences, genetics, or changes in brain networks. But over the last several decades, researchers have added another important piece to the puzzle: the immune system.
A growing body of evidence suggests that inflammatory pathways in depression research may help explain symptoms in a biologically distinct subgroup of people.
Studies have reported higher average levels of inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) in depression, although these changes are far from universal.
This does not mean depression is simply an inflammatory disease. Major depressive disorder is highly heterogeneous, and many people with depression do not show significant systemic inflammation.
Instead, scientists are studying how immune signals interact with stress hormones, neurotransmitters, microglia, reward circuits, and neural plasticity.
These connections may eventually help researchers identify different biological subtypes of depression and develop more personalized treatments.
Why Researchers Are Interested in Inflammation and Depression
Inflammation is one of the body’s basic defense mechanisms.
When you develop an infection or experience an injury, immune cells release chemical messengers called cytokines. These signals help coordinate the immune response and encourage behaviors that conserve energy while the body recovers.
You may feel tired, lose interest in socializing, experience reduced appetite, or struggle to concentrate when sick.
Interestingly, these “sickness behaviors” overlap with several symptoms of depression.
Researchers have therefore investigated whether persistent low-grade inflammation could influence mood and motivation even when someone does not have an obvious infection.
A 2019 meta-analysis involving more than 13,000 people with depression estimated that around 27% had CRP levels above 3 mg/L, a commonly used threshold for low-grade inflammation. More than half had CRP above 1 mg/L.
These figures highlight an important point: inflammation may matter for a substantial subgroup, but it is not present at the same level in everyone with depression.
Cytokines Create a Communication Bridge With the Brain
For a long time, the brain was considered relatively isolated from immune activity elsewhere in the body.
We now know the communication is much more dynamic.
Peripheral immune activation can influence the brain through several routes, including circulating signals, neural pathways such as the vagus nerve, changes at the blood-brain barrier, and immune-cell communication.
Cytokines such as IL-6, IL-1β, and TNF-α are among the molecules researchers study most closely.
A major review in Nature Reviews Immunology described how inflammatory signaling can influence neurotransmitter metabolism, neuroendocrine activity, neural circuits, and behavior.
Think of cytokines as part of a messaging system.
During a short-term infection, those signals are useful. They tell the body and brain to temporarily change priorities.
Problems may arise when inflamatory signaling remains elevated longer than necessary.
Under certain conditions, persistent immune activity may contribute to fatigue, anhedonia, slower thinking, altered sleep, and changes in motivation that resemble or intensify depressive symptoms.
Microglia Connect Immune Activity With Brain Function
The brain also has its own resident immune cells.
These cells are called microglia.
Under normal conditions, microglia help maintain the neural enviroment, clear cellular debris, respond to injury, and participate in synaptic remodeling.
When inflammatory signals become persistent, microglial activity can change.
Researchers are studying whether prolonged microglial activation contributes to altered neurotransmission, oxidative stress, synaptic function, and neural plasticity in some forms of depression.
A 2023 review of major depressive disorder described several potential routes through which peripheral inflammation may influence neuroinflammation, including cytokine signaling, microglial activity, the gut-brain axis, and alterations in glial function.
However, scientists need to be careful with the term “brain inflammation.”
Depression does not generally involve the same dramatic inflammatory process seen in infections such as encephalitis.
Researchers are usually discussing subtler neuroimmune changes involving signaling pathways and immune-cell activity.
That distinction prevents an interesting research hypothesis from turning into an oversimplified explanation.
The Kynurenine Pathway May Link Inflammation to Neurotransmitters
One of the most fascinating mechanisms being investigated involves the amino acid tryptophan.
Tryptophan can be used to produce serotonin, but it can also enter another metabolic route called the kynurenine pathway.
Inflammatory cytokines can influence enzymes involved in this pathway.
As immune activity increases, tryptophan metabolism may shift toward kynurenine and several downstream metabolites.
Some of those metabolites appear relatively protective, while others – such as quinolinic acid – can influence glutamate signaling and potentially contribute to oxidative or excitatory stress under certain conditions.
Research reviews suggest that altered kynurenine metabolism may represent one pathway connecting immune activation with depressive symptoms, although findings in peripheral blood and different brain regions are not always consistant.
This pathway also demonstrates why saying “depression is caused by low serotonin” is far too simple.
Immune activity may influence several neurotransmiter systems simultaneously, including serotonin, dopamine, and glutamate.
Chronic Stress Can Activate Immune Pathways Too
Inflammation does not always begin with an infection.
Psychological stress can also interact with the immune system.
Short-term stress activates the sympathetic nervous system and hypothalamic-pituitary-adrenal, or HPA, axis. Cortisol normally helps regulate immune activity.
Under chronic stress, however, this regulation can become more complicated.
Long-term stress has been associated with changes in immune signaling, glucocorticoid sensitivity, sympathetic activity, and inflammatory responses.
Researchers have proposed that persistent stress may therefore create a pathway from psychological experiences to biological changes that influence mood.
This is not a simple one-directional chain.
Sleep disruption, obesity, smoking, physical illness, inactivity, social stress, medication, genetics, and many other factors can influence inflammatory markers.
For example, a large UK Biobank analysis found higher CRP levels among people with depression, but lifestyle and health variables explained part of the association. A smaller difference remained after statistical adjustment.
In other words, depression and inflammation probably influence each other within a broader biological and behavioral system.
Inflammation May Affect Reward and Motivation Circuits
One reason inflammation research is particularly interesting involves anhedonia—the reduced ability to experience interest, motivation, or pleasure.
Inflammatory signaling can affect dopamine-related pathways involved in reward processing.
Research suggests these effects may influence circuits connecting the ventral striatum and prefrontal regions, potentially changing how rewarding an activity feels relative to the effort required.
From an evolutionary perspective, that makes sense.
When the body is fighting an infection, conserving energy rather than exploring the world may be useful.
You rest instead of socializing. Physical effort feels more expensive. Motivation drops.
But if similar immune signals remain elevated without a short-term infection to resolve, the same energy-conservation response could become maladaptive.
A major review of inflammation in depression has linked inflammatory effects on dopamine and other neurotransmitter systems with changes in neural circuits supporting motivation, motor activity, anxiety, and threat processing.
This may explain why researchers are increasingly interested in matching biological inflammatory profiles with specific symptoms rather than treating depression as one uniform condition.
Biomarkers Could Help Identify an Inflammatory Subtype
Could doctors eventually use a blood test to identify “inflammatory depression”?
That is one of the major questions in the field.
CRP is attractive because it is inexpensive and routinely measured in medical settings. Researchers also investigate IL-6, TNF-α, other cytokines, immune-cell patterns, and metabolic markers.
Meta-analytic evidence consistently shows higher average CRP and IL-6 levels in groups with depression compared with healthy controls.
But group averages are not the same as diagnostic tests.
An elevated CRP result can occur because of infection, obesity, autoimmune disease, smoking, injury, or many other factors. A normal result also does not rule out depression.
For now, inflammatory biomarkers are more useful as research tools than as stand-alone clinical tests for diagnosing depression.
The longer-term goal is more precise.
Researchers hope biomarkers might eventually help distinguish patients whose symptoms are strongly associated with immune dysregulation from those whose depression follows different biological pathways.
Could Anti-Inflammatory Treatments Help Depression?
If inflammation contributes to depression in some people, an obvious question follows: can reducing inflammation improve symptoms?
Researchers have tested several approaches, including cytokine inhibitors, anti-inflammatory medications, minocycline, statins, and other agents.
Results have been promising in some studies but inconsistent overall.
A 2023 systematic review of existing meta-analyses concluded that several anti-inflammatory approaches showed antidepressant effects, yet differences in patient populations, study quality, drugs, and treatment protocols prevented clear general clinical recommendations.
More recent evidence has strengthened the idea that patient selection may matter.
A 2025 systematic review and meta-analysis specifically examining depressed participants with elevated inflammation found that anti-inflammatory treatments may reduce depressive symptoms and anhedonia in this subgroup.
That does not mean people with depression should start taking anti-inflammatory drugs themselves.
These medications can have significant side effects, and inflammation is only one potential mechanism among many.
Instead, these findings support a more interesting possibility: future depression treatment may become increasingly personalized according to underlying biology.
Understanding inflammatory pathways in depression research adds another layer to an already complex condition.
Cytokines, microglia, the kynurenine pathway, HPA-axis signaling, dopamine circuits, and neural plasticity may all interact when immune activity becomes chronically elevated.
But inflammation is not a universal explanation for depression.
Evidence points toward inflammatory changes in a subgroup of patients, which is why researchers are increasingly studying biomarkers and individualized treatment responses rather than searching for one mechanism that explains everyone.
The next major step is identifying who actually benefits from inflammation-targeted interventions and which biomarkers can reliably guide treatment.
For readers, the key takeaway is simple: depression involves communication between the brain and the rest of the body – and immune biology is becoming an increasingly important part of that conversation.
